PUR.WAR Pure Biologics Spólka Akcyjna

Biotechnology Warsaw Stock Exchange
1.38 PLN
Close of Oct 29, 2026
1.37 5.85
Market cap
PLN 35.9M
P/E
-
P/B
0.75x
ROE
-
Dividend yield
-
Fundamental score
0.7/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.

Is PUR.WAR undervalued?

Graham number

The Graham number of Pure Biologics Spólka Akcyjna cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Pure Biologics Spólka Akcyjna fundamental analysis

4 of 21 checks passed

ROE 0/2

ROE cannot be calculated: equity is negative or not reported.

ROA 0/1

Return on assets (-564.9%) is below the industry median (-18.6%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (64.2%) is above the industry median (2.6%).

Revenue Growth 0/2

Revenue did not grow over the past 3 years or is not reported.

Short-term Liquidity 0/1

Current assets do not cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Cash Runway 0/2

Cash covers 0.1 years of the current cash burn.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 1/1

Price to book (1.6x) is below the industry median (3.6x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Pure Biologics Spólka Akcyjna stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Pure Biologics Spólka Akcyjna

Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFß1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the aVß8 integrin. The company was founded in 2010 and is based in Wroclaw, Poland.

Full company profile